Reverse DCF
What growth does the market imply for AMBUJACEM?
Working backwards from the current price to find the FCF growth assumption baked in.
conservative
4.8% implied annual FCF growth
The market is pricing in below-GDP growth — very conservative assumption. If the company delivers anywhere near its historical rate, there is significant upside.
Current Price
₹456
Historical Growth
20.0%
FCF Yield
4.94%
Price / FCF
20.2x
Plain English
To justify today's price of $456.10, AMBUJACEM.NS needs to grow its free cash flow at 4.8% per year for the next 10 years. That is 15.2% slower than its historical growth rate of 20.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 2.4% | ₹378 | -17.2% |
| Implied | 4.8% | ₹453 | -0.6% |
| GDP rate | 10.0% | ₹677 | +48.5% |
| Historical | 20.0% | ₹1,478 | +224.1% |
At Historical Growth Rate
It would take 3 years for AMBUJACEM to organically grow into today's price assuming its historical FCF growth of 20.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.